Core Viewpoint - Annovis Bio, Inc. has announced a registered direct offering to sell 4,000,000 shares of its common stock at a price of $1.50 per share, aiming to raise approximately $6 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close around October 13, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering are anticipated to be about $6 million before deducting fees and expenses [2]. Group 2: Regulatory Information - The securities are being offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on February 1, 2024, and declared effective on February 12, 2024 [3]. - A prospectus supplement and base prospectus related to the offering will be filed with the SEC and made available on their website [3]. Group 3: Company Overview - Annovis Bio is focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, with a commitment to improving patient outcomes [5].

Core Insights - Annovis Bio, Inc. is a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease [1][4] Group 1: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania and is dedicated to addressing neurodegeneration in diseases like Alzheimer's and Parkinson's [4] - The company aims to develop innovative therapies that improve patient outcomes and quality of life [4] Group 2: Upcoming Events - CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel [1] - Interested parties can schedule one-on-one meetings with Dr. Maccecchini through the conference portal [3]